On March 14, 2022, Weil achieved a sweeping victory for client CareDx following a five-day jury trial in Delaware federal court, when a jury returned a nearly $45M verdict in CareDx’s favor against competitor Natera. The jury found that Natera intentionally and willfully engaged in false advertising in the promotion of its kidney transplant rejection assessment test that deliberately deceived the organ transplant community, and awarded CareDx $21.2M in compensatory damages and $23.7M in punitive damages under the Lanham Act, the Delaware Deceptive Trade Practices Act and Delaware unfair competition law.

The Weil team was led by Patent Litigation Co-Head Edward Reines and included associate Liz McLean.